Fig. 6: CDC25A and DYRK2 are functionally linked in response to DNA damage.

A Lysates from MOR cells treated with increasing adriamycin (ADR) concentrations (1, 2, 4, and 6 μM) for 24 h were analyzed by WB. A representative experiment of three performed is shown. B HEK-293T cells were transfected with DYRK2 siRNAs or siRNA control and incubated with adriamycin (ADR; 6 μM) for 24 h after 3 days of transfection. The expression of proteins was analyzed by WB. C HeLa cells derived from DYRK2-KO cells and DYRK2-KO cells reconstituted with the indicated proteins were incubated with Adriamycin and viability assayed in clonogenic assays. Representative pictures are shown. Quantification of the data is shown in the bar graph (mean ± SD, n = 3; *P < 0.05, **P < 0.01). The expression of the indicated proteins was assessed by WB. D Transfected H1299 cells were treated with Etoposide (10 μM) for 24 h at 36 h post-transfection and the percentage of apoptotic cells was determined by Annexin V/PI staining (mean ± SD, n = 3; *P < 0.05, **P < 0.01, ***P < 0.001). E HeLa cells, derived DYRK2-KO cells and DYRK2-KO cells overexpressing Flag-CDC25A or pretreated with CDC25A inhibitor NSC-95397 (32 nM) for 30 min were incubated with adriamycin (3 μM) for 6 h, and viability assayed in clonogenic assays. Representative pictures are shown. Quantification of the data is shown in the bar graph (mean ± SD, n = 3; *P < 0.05, ***P < 0.001). The expression of the indicated proteins was assessed by WB.